ArticleHealth science reports2025
Adrenal Insufficiency Associated Cardiomyopathy, From Molecule to Clinic: A Comprehensive Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A rare case report of familial glucocorticoid deficiency type 4 (GCCD4) with dilated cardiomyopathy: a 3-year follow-up study.Translational pediatrics · 2026Article
- Article
- Advances and unmet needs in pharmacologic therapy for pediatric heart failure: Insights from the 2025 International Society for Heart and Lung Transplantation Guidelines.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Adrenal insufficiency (AI), the lack of glucocorticoids (GCs) production or function with or without a lack of mineralocorticoids (MCs) and adrenal androgens, can result in uncommon but life-threatening complications like shock, circulatory failure, syncope, arrhythmias, dilated cardiomyopathy (DCM), and congestive heart failure (CHF). In this article, we aim to comprehensively review the cardiomyopathy (CMP) secondary to AI. Methods: This review focused on CMP secondary to AI. A systematic search was conducted in Pubmed, GoogleScholar, and Embase. The relevant articles were included in this review. Results: All three kinds of AI-primary, secondary, and tertiary-have been associated with CMP. AI can cause takotsubo CMP, lethal arrhythmias, and DCM. There have been reports of CMP in all three kinds of AI: primary, secondary, and tertiary. AI can manifest as newly developed systolic HF and contribute to cardiovascular disease. When adrenal replacement therapy is started in patients with adrenal failure, heart function improves quickly. Early detection could stop this phenomenon from happening again. Conclusion: Herein, we provided an overview of AI-associated CMP regarding underlying causes, pathophysiology, associated symptoms, diagnosis, and treatment of AI-associated CMP. Adrenal replacement therapy can quickly improve heart function. More research is needed to explore the effects of GCs and MCs on the heart and to better understand associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.